

Cubatha				Complete if Known					
Substitute for fo	orm 1449A/B/PTO			Application Number	Unassigned 10808277				
INFO	DRMATION	DISCI	OSURE	Filing Date	March 23, 2004				
	TEMENT B			First Named Inventor	Joseph A. HRABIE				
017	I LINILIA I D	IAFF	LICANI	Group Art Unit	Unassigned 1624				
	(Use as many shee	ts as nece:	ssary)	Examiner Name	Unassigned PATE				
Sheet	1	of	1	Attorney Docket Number	227957				

Doc. No.	U.S. Patent Do	cument			1
	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of	Filing Date If Appropriate
AA	4,954,526	US	Keefer		
AB	5,155,137	US	Keefer et al.		
AC	5,212,204	US	Keefer et al.	05-18-93	
	No. AA AB	Doc. Application or Patent Number A A 4,954,526 A B 5,155,137	No. Patent Number Kind Code AA 4,954,526 US AB 5,155,137 US	U.S. Patent Document Doc. Application or Patent Number Kind Code Name of Patentee or Applicant AA 4,954,526 US Keefer AB 5,155,137 US Keefer et al.	Doc. Application or Patent Number Kind Code Name of Patentee or Applicant Date of Publication AA 4,954,526 US Keefer 09-04-90 AB 5,155,137 US Keefer et al. 10-13-92

				FORE	IGN PATENT DOCUMENTS			
		Foreign Patent Document					Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
80	ΑD	WO	93/13055		Wellcome Found.	07-08-93		"
100	ΑE	WO	94/27957		Univ. California	12-08-94		
2	AF	WO	95/05363		Fisons Corp.	02-23-95		
000	AG	wo	96/40665		Gov. of U.S.	12-19-96		
m	AH	DD	122,080		Ohme et al.	09-12-76		

Examiner	Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item						
Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.						
SY O	AI	BOGDAN C., PubMed Abstract 11577346, also cited as <i>Nat. Immunol., 2(10)</i> , 907-916 (2001)		_				
	ΑJ	CHABRIER et al., PubMed Abstract 10442086, also cited as Cell. Mol. Life Sci., 55(8-9), 1029-1035 (1999)						
	AK	Derwent Abstract AN-85-047728, Derwent Publications Ltd., "New N, N'-dihydroxydiazenium Propanol Derivative for Prevention and Treatment of Apple Canker" (January 14, 1985)						
	AL	FELDMAN et al., C&EN, 26-38 (1993)						
L	AM	FREEMAN et al., "Alkaline Decomposition of Nitrosohydroxylamine Derivatives," J. Org. Chem., 35(9), 3107-3110 (1970)						
	AN	LE CORVOISER et al., PubMed Abstract 11324316, also cited as J. Soc. Biol., 194(3-4), 143-149 (2000)						
	AO	NATHAN C., FASEB, 6, 3051-3063 (1993)						
	AP	OKA et al., PubMed Abstract 12909236, also cited as Int. J. Radiat. Oncol. Biol. Phys., 57(1), 217-221 (2003)	_					
	AQ	TURUNEN et al., PubMed Abstract 10817812, also cited as Exp. Gerontol., 34(4), 567-574 (1999)						
1	AR	VOLODARSKII et al., "Preparation and Properties of N-nitroso-alpha-hydroxylamino Oximes," Chemical Abstracts, 85(21), abstract no. 15959w (1976)						
80	AS	WANG et al., PubMed Abstract 12856639, also cited as <i>Urol. Oncol.</i> , 21(2), 117-122 (2003)						

Examiner Signature

Date Considered

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type		gn (+) inside	this box —		ار از از	10 30 S							
Substitute for form 1449A/B/PTO							Complet if Known						
Substitute for form 1449A/B/PTO							Application Number	10/349,	2 28 10808	27	7		
IN.	NFOR	MATI	ON DISC	:LOŠ	PP	ARK	Filing Date	January 22, 2003 3 1 2 3 1 0 4					
			T BY AP				First Named Inventor	Joseph A. HRABIE					
				LIO	Z14 1		Group Art Unit	1624					
	(U.	se as man	y sheets as ned	essary)			Examiner Name	Sudhak	Sudhaker B. Patel				
Sheet	<u>t </u>	1	of		1		Attorney Docket Number	220914	0914				
			U.S. Patent Do		U.	S. PAT	ENT DOCUMENTS						
Examiner	r Doc.		plication or				•	1					
Initials					lame of Patentee or Applica	nt	Date of Publication	Filing Date If Appropriate					
120	AL	4,954	,526	US	L	arry K	. Keefer		9-4-90	2-28-89			
		-		 _									
	4	 		<u> </u>							/		
		-											
$\overline{}$	+			<u> </u>						/			
	+										*		
	+	+		 									
	`	/											
	1	1		 	- 	~		 -	/	,			
		—			- -				/				
	1		/	 									
							· · · · · · · · · · · · · · · · · · ·	-/-					
								$\overline{}$					
							7						
	ļ								· · · · · · · · · · · · · · · · · · ·	-			
	 	 											
	-}	<u> </u>			7								
		1			-				·				
							_/						
		Τ .	oreign Patent	Doors	FORE	IGNRA	ATENT DOCUMENTS	•					
Examiner	Doc.		Application	on or	Kind	/				Trans	slation		
Initials	No.	Office	Patent Nu	mber	Code	<u> </u>	Name of Patentee or Appli	cant	Date of Publication	Yes	No*+		
	 	ļ	ļ		_/_								
	 		···										
	 			-4									
	 			/						-			
		<u> </u>		<u></u>					L				
				OTHER	- NON	PATEN	T LITERATURE DOCUMEN	ITS					
Examiner Dog Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate) title of the includence of the author (in CAPITAL LETTERS) title of the article (when appropriate) ti									Trans	lation			
initials	No.	(book, m	jagazine, journa	al, serial, s	ymposiu	ım, cata	3100. etc.), date, page(s), vol	20. etc.), date. page(s), volume-issue humber (e), public		Yes	No++		
		city and/or country where published.								1.03	140.		
		/-		<u></u>						 			
										 	——		
			·							1	——		
	<u> </u>								· · ·	1			

Examiner Signature

Date Considered

04

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).